Verve Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	0.15	0.23	0.13	0.67
Cash & Short-Term Investments	0.15	0.23	0.13	0.67
Cash Growth	-78.20%	73.42%	-80.68%	-
Accounts Receivable	0.24	0.53	0.61	3.84
Other Receivables	0.45	0.23	0.05	0.09
Receivables	0.69	0.76	0.66	3.93
Prepaid Expenses	0.01	0.01	0.02	0.01
Other Current Assets	-	-	0.11	-
Total Current Assets	0.84	1	0.92	4.61
Property, Plant & Equipment	24.09	23.87	0.09	0.06
Long-Term Investments	0.02	0.09	0.28	0.11
Long-Term Accounts Receivable	-	-	5.65	1.6
Other Long-Term Assets	3.08	2.8	-	-
Total Assets	28.03	27.75	6.94	6.38
Accounts Payable	1.67	2.01	0.39	0.68
Accrued Expenses	2.25	0.19	0.2	0.47
Short-Term Debt	-	-	-	0.7
Current Portion of Long-Term Debt	0.76	0.49	0.99	0.79
Current Portion of Leases	2.47	2.38	-	-
Current Unearned Revenue	0.37	0.19	0.48	0.49
Other Current Liabilities	-	0.09	0.09	0.13
Total Current Liabilities	7.51	5.36	2.15	3.26
Long-Term Debt	10.4	10.65	3.31	1.49
Long-Term Leases	12.91	13.3	-	-
Total Liabilities	30.82	29.31	5.46	4.75
Common Stock	0.28	0.24	0.24	-
Additional Paid-In Capital	0.04	0.04	-	-
Retained Earnings	-3.1	-1.84	1.25	1.63
Shareholders' Equity	-2.78	-1.56	1.48	1.63
Total Liabilities & Equity	28.03	27.75	6.94	6.38
Total Debt	26.53	26.83	4.3	2.98
Net Cash (Debt)	-26.38	-26.6	-4.17	-2.31
Net Cash Per Share	-0.11	-0.11	-0.02	-
Filing Date Shares Outstanding	279.85	279.85	30.08	-
Total Common Shares Outstanding	279.85	237.87	30.08	-
Working Capital	-6.66	-4.36	-1.23	1.35
Book Value Per Share	-0.01	-0.01	0.05	-
Tangible Book Value	-2.78	-1.56	1.48	1.63
Tangible Book Value Per Share	-0.01	-0.01	0.05	-
Machinery	7.38	6.68	0.11	0.06

Source: S&P Global Market Intelligence. Standard template. Financial Sources.